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Abstract
The bioactive peptides of the apelinergic system and its receptor APJ have
been shown to play a protective role in experimental cardiovascular and dia-
betic kidney disease (DKD). Mechanisms of this renoprotective effect remain
to be elucidated. In this study, we examined the localization of APJ within the
normal kidney and its kidney expression in the db/db model of DKD. The
effect of hyperglycemia and angiotensin II on APJ was examined in cultured
podocytes. In the glomerulus, APJ colocalized with podocyte but not endothe-
lial cell markers. In podocytes stimulated with Pyr1Apelin-13, a change in the
phosphorylation status of the signaling proteins, AKT, ERK, and p70S6K, was
observed with an increase 15 min after stimulation. Apelin-13 decreased activ-
ity of Caspase-3 in podocytes after high glucose treatment reflecting an anti-
apoptotic effect of APJ stimulation. In podocytes, APJ mRNA was
downregulated in high glucose, when compared to normal glucose conditions
and exposure to angiotensin II led to a further significant decrease in APJ
mRNA. APJ and preproapelin mRNA levels in kidneys from db/db mice were
markedly decreased along with decreased tubular APJ protein by western blot-
ting and immunostaining when compared to db/m controls. In conclusion,
the apelinergic system is decreased in kidneys from db/db mice. Within the
glomerulus, APJ is mainly localized in podocytes and in this cell type its acti-
vation by Apelin-13 abolishes the proapoptotic effect of high glucose, suggest-
ing a potential therapeutic role of apelin and emerging agonists with extended
half-life for therapy of DKD.
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Introduction
APJ is a G protein-coupled receptor consisting of seven
transmembrane domains, that shares a 31% identical
amino acid sequence with angiotensin AT1 receptor, but
does not bind angiotensin II (Ang II) (Huang et al.
2018). Messenger RNA (mRNA) molecules for pre-
proapelin and APJ are expressed in human tissues such
as stomach, brain, heart, kidney, adipose tissue, lung,
and in human endothelial cells (Hosoya et al. 2000;
O’Carroll et al. 2000; Medhurst et al. 2003; Kleinz and
Davenport 2004; Kleinz et al. 2005). The Apelin gene
encodes an initially translated 77-aa preproprotein,
which is cleaved by proteases to shorter forms, such as
Apelin-36, -17, -13 or -the more resistant to degrada-
tion- pyroglutamate form of Apelin-13 (Pyr1Apelin-13)
(Medhurst et al. 2003; De Mota et al. 2004). The biolog-
ical importance of Apelin as a peptide is suggested by its
wide tissue distribution and the strict conservation of
the last 13aa at the C-terminus (65-77aa) among all spe-
cies studied (Tatemoto et al. 1998; Habata et al. 1999;
Lee et al. 2000). In the cardiovascular system, both Ape-
lin and APJ are present in cardiac myocytes and vascular
smooth muscle cells (Kleinz and Davenport 2004; Hashi-
moto et al. 2006). The therapeutic potential of apelins in
cardiovascular disease and preeclampsia is a topic of
great interest (Kalea and Batlle 2010; Yamaleyeva et al.
2015, 2016; Zhe et al. 2016). Also of interest is a recent
report that has shown that aging promotes and it is later
characterized by a state of multiorgan apelinergic defi-
ciency (Rai et al. 2017).
In the rat kidney APJ, mRNA expression has been
reported (Hosoya et al. 2000; O’Carroll et al. 2000). APJ
is highly expressed in the inner stripe (IS), intermediate
in the outer stripe (OS) and in the inner medulla (IM)
and, lowest in the cortex (Hus-Citharel et al. 2008).
O’Carroll et al. (2000) found that labeling in the kidney
cortex corresponded to an APJ mRNA expression in
40% of the glomeruli, and suggested a role for this
receptor in the regulation of blood flow. Studies focusing
on the vasculature showed that the apelinergic system
regulates Ang II - AT1 receptor signaling (Susztak et al.
2006). It is possible that at the kidney level Apelin may
also play a counterregulatory role on the actions of Ang
II. In kidneys, studies on the role of Apelin and APJ in
renal hemodynamics showed that Apelin increases
medullary blood flow by inducing a vasodilatory effect
in agreement with the opposing actions against Ang II
regarding blood pressure (Ishida et al. 2004) and vascu-
lar tone (Gurzu et al. 2006; Zhong et al. 2007). Apelin
has been shown to be protective against acute renal
injury (Chen et al. 2015) and diabetic kidney disease
(DKD) (Day et al. 2013). Day, Cavaglieri, and Feliers
(Day et al. 2013) showed that Apelin-13 reduces
glomerular hypertrophy and inflammatory markers in
the OVE26 model of type 1 diabetes. Our study was
aimed at determining the localization of the APJ recep-
tor within the kidney glomerulus and examining its reg-
ulation by hyperglycemia and Ang II as well as signaling
by apelin-13 using cultured podocytes. Finally, the db/db
mouse was used to examine the kidney expression of the
apelinergic system in a model of type 2 diabetes.
Materials and Methods
Animal model and tissue preparation
Obese db/db mice (C57BLKS/JLepr) were used as a
model of type 2 diabetes and their lean littermates (db/
m) served as nondiabetic controls (Jackson Laboratory,
Bar Harbor, ME). We used young (8 weeks of age)
female db/db mice to study an early phase of diabetes
(3–4 weeks of onset) and 24–32 weeks old female db/db
mice which exhibit kidney lesions consistent with early
diabetic nephropathy (Lee and Bressler 1981). The Insti-
tutional Animal Care and Use Committee approved all
procedures. Kidneys and hearts from these mice were
removed quickly, cut longitudinally, and half of kidney
and heart sections were stored at 80°C for protein and
RNA analysis. The remaining half of kidney sections
were fixed with 10% buffered formalin phosphate (Fisher
Scientific, Hanover Park, IL) overnight. After paraffin
embedding, tissue sections (4 lm) were deparaffinized in
xylene and rehydrated through graded ethanol series
before use.
Kidney histology
For histological evaluation, kidneys were cut longitudi-
nally and fixed with 10% buffered formalin phosphate
(Fisher Scientific, Pittsburg, PA). Paraffin sections were
stained with hematoxylin and eosin and periodic
acid-Schiff. Glomerular hypertrophy was quantified by
measuring the glomerular tuft cross-sectional area with
a computer image analysis system (Image J, NIH).
Glomerular hypertrophy was assessed by measuring the
tuft area from glomeruli in which the vascular pole was
evident (using 20 glomeruli per section). This was per-
formed to reduce the possibility of including tangen-
tially cut glomeruli (Soler et al. 2007). Glomerular
images were obtained digitally using Tissue Gnostic
Acquisition platform. Total glomerular area was traced,
and calculated using Image J (NIH) analysis software.
Mesangial matrix expansion and glomerular cellularity
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was graded by a masked renal pathologist using a semi-
quantitative score.
Preparation of RNA and protein extracts
Kidney and heart sections were used to extract total RNA
using TRIZOL (Thermo Fisher Scientific, Waltham,
MA) following the manufacturer’s instructions. Total
RNA was quantified and tested for purity by optical den-
sity (OD) absorption ratio OD260 nm/OD280 nm with a
spectrophotometer (GeneQuant Pro, Biochrom, Cam-
bridge, United Kingdom). RNA was reverse transcribed
using Reverse Transcription Kit (Thermo Fisher Scientific,
Waltham, MA) following manufacturer’s protocols and
cDNA was stored at 20°C for further analysis. For pro-
tein extracts, kidney sections were washed with PBS over
ice and protein was extracted using mammalian protein
extraction buffer (MPER, Pierce) supplemented with a
protease inhibitor cocktail (Sigma-Aldrich, Saint Louis,
MO) and PMSF, following manufacturer’s instructions.
Protein concentrations in protein homogenate super-
natants were measured with the BCA assay method
(Pierce, Rockford, IL). Supernatants were stored at
70°C and used for detection of proteins of interest.
Reverse Transcription and RT-qPCR
Constant amounts of 2.5 lg of extracted kidney and heart
RNA were reverse transcribed to synthesize complementary
DNA (cDNA). Synthesis of cDNA was performed using
Reverse Transcription Kit on a GenAmp PCR System 9700
(both Thermo Fisher Scientific, Waltham, MA) with stan-
dard cycling parameters. The mRNA expression for the
genes of interest was quantified by RT-qPCR on a 96-well
plate using a TaqMan Gene Expression Master Mix on a
Step One Plus PCR System (both Thermo Fisher Scientific,
Waltham, MA). PCR reactions were carried out using
Assays-on-DemandTM Gene Expression Products (Thermo
Fisher Scientific, Waltham, MA) following the suggested
RT-qPCR protocol for all investigated factors: denatura-
tion for 10 min at 95°C, 40 cycles of a three segmented
amplification and quantification program (denaturation
for 10 sec at 95°C, annealing for 15 sec at the primer-spe-
cific temperature (95°C), annealing/extension for 1 min at
60°C). Reactions were performed in duplicates. mRNA
expression for preproapelin and APJ was normalized
against glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) mRNA expression. GAPDH was chosen as
internal control, since the levels were consistent among
kidney and heart tissues as described in previous reports
(Medhurst et al. 2003). Primers were ordered from
Thermo Fisher (GADPH: Mm99999915_g1; APJ:
Mm00442191_s1; Preproapelin: Mm00443562_m1).
Western Blot
Protein expression for APJ was studied using protein
extracts from mouse kidney lysates (~20 lg), which were
separated on 10% Bis-Tris Novex precast gels (Thermo
Fisher Scientific, Waltham, MA) with MOPS buffer, after
denaturation in reducing sample buffer. Proteins were
transferred to treated 0.4 lm PVDF membranes (Milli-
pore, Billerica, MA) which were blocked using 5% nonfat
dry milk in 0.1% v/v Tween-30 Tris-buffered saline (TBS-
T), and later were immunoblotted using a primary anti-
body for APJ (goat polyclonal IgG 1:500, raised against a
peptide mapping within a C-terminal cytoplasmic domain
of APJ, Santa Cruz Biotechnologies, Dallas, TX) and its
corresponding HRP-linked secondary antibody. The
respective blocking peptide for APJ was used on the same
membrane to verify the specificity of the bands detected
in kidney samples. For further studies, we focused on the
42 kDa band, based on the reported molecular size of the
monomeric APJ (Cai et al. 2017) and the uncertainty as
to the identity of the extra bands which were also erased
by the blocking peptide in kidney lysates (Fig. 1). A posi-
tive control with 293T whole cell lysate from cells trans-
fected with human APJ was also used (Santa Cruz
Biotechnologies, Dallas, TX) along with the kidney sam-
ples (Fig. 1).
In all experiments, detection of signal was performed
using Amersham ECL Plus reagents, and films were devel-
oped and quantified by densitometry using ImageJ Soft-
ware. In many cases, to confirm equal loading of total
protein into each lane, membranes were stripped and
probed for the control protein b-tubulin (rabbit polyclonal
IgG for b-tubulin, Santa Cruz Biotechnologies, Dallas, TX).
Immunohistochemistry
Kidney sections (4 lm) were deparaffinized and rehy-
drated. Antigen retrieval was performed with a pressure
cooker at 120°C in target retrieval solution (Agilent Tech-
nologies, Santa Clara, CA). Endogenous peroxidase activity
was blocked with 3% hydrogen peroxide (Thermo Fisher
Scientific, Waltham, MA). The primary antibodies for
anti-APJ (1:100; rabbit antibody, Neuromics, Edina, MN)
and WT-1 (1:400; rabbit antibody, Santa Cruz Biotechnol-
ogy, Dallas, TX) were applied overnight and one slide in
each set of experiments was incubated only with nonim-
mune serum to be used as negative control to evaluate
specificity. Sections for APJ and WT-1 staining were
washed and incubated with goat anti-rabbit IgG conju-
gated with peroxidase-labeled polymer (Agilent Technolo-
gies, Santa Clara, CA). Peroxidase labeling was revealed
using a liquid diaminobenzidine substrate-chromagen sys-
tem (Agilent Technologies, Santa Clara, CA). Sections
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were counterstained with hematoxylin (Sigma-Aldrich,
Saint Louis, MO) and dehydrated, mounted with Per-
mount (Thermo Fisher Scientific, Waltham, MA), and
cover-slipped. For anti-APJ staining, sections were exam-
ined and photographed with a Nikon Eclipse 50i micro-
scope for semiquantitative and qualitative observations
and comparisons. For assessment of the intensity of APJ
kidney staining, a semiquantitative analysis of the
immunoperoxidase stained sections was done based on
fooling scale: 0- no staining; 1-weak staining; 2-strong
staining. Sections were examined independently by two
observers, who assessed staining intensity from each slide
of either five viewing fields (for tubular staining) or 25
glomeruli (for glomerular tuft staining). A composite score
was then generated for each mouse to compare APJ stain-
ing in db/m and db/db mice.
For podocyte count, two masked observers counted WT-
1 stained nuclei in 20 glomeruli from each kidney section.
Confocal immunofluorescence microscopy
The paraffin-embedded kidney sections (4 lm) were
deparaffinized and rehydrated. After antigen retrieval, sec-
tions were permeabilized with 0.5% Triton-X100 in PBS
for 5 min and blocked with 5% normal donkey serum in
PBS for 1 h at room temperature in a humidified slide
chamber. The sections were incubated with primary anti-
bodies diluted in 5% donkey serum in PBS overnight at
4°C. The primary antibodies used for the immunofluores-
cence were anti-APJ (1:200; rabbit antibody, Neuromics,
Edina, MN) and one of the specific cell type markers. For
the APJ antibody used for IF, there is no commercially
available peptide immunogen. This anti-APJ antibody,
however, had been validated by the producer using APJ-
transfected COS-7 cells (Neuromics, Data Sheet). More-
over, in a study by Farkasfalvi et al. (2007) in addition to
the antibody, we used a second APJ antibody directed
against a different region of the receptor to ensure robust
results. They determined that both antibodies showed the
same staining pattern and hence both were equally specific.
As podocyte markers, we used antinephrin (1:100; Santa
Cruz Biotechnologies, Dallas, TX), which localizes specifi-
cally in the slit diaphragm (Zhang et al. 2004); an antibody
against synaptopodin (1:100; Santa Cruz Biotechnologies,
Dallas, TX), which is an actin-associated protein in the
podocyte foot process (Thomas et al. 1994); antipodocin
(diluted 1:100; Santa Cruz Biotechnologies, Dallas, TX),
which is specific for the basal pole of podocyte along the
glomerular basement membrane (Roselli et al. 2002) as
well as anti-WT-1 (diluted 1:100; Santa Cruz Biotechnolo-
gies, Dallas, TX) and DAPI (Santa Cruz Biotechnologies,
Dallas, TX), for specific podocyte nuclear staining. Plate-
let-endothelial cell adhesion molecule (PECAM-1) anti-
body (1:100; Santa Cruz Biotechnologies, Dallas, TX) was
used as an endothelial cell marker of glomerular endothe-
lial cells and a-smooth muscle actin antibody (diluted
1:200; Sigma-Aldrich, Saint Louis, MO) was used to stain
vascular smooth muscle (Ye et al. 2006). Desmin, a gift
from J Meiner, was used as a marker of mesangial cells
(Lin et al. 2018). Antibodies against ACE2 (diluted 1:200,
affinity purified (Ye et al. 2006)), ACE (Ye et al. 2006) and
aquaporin 2 (diluted 1:200, Santa Cruz Biotechnology,
Dallas, TX) were used for colocalization studies within
proximal and collecting tubules. Sections were washed with
Figure 1. Immunoblot analysis for APJ in mouse kidneys (n = 3) without (left) and with (right) blocking peptide incubation. MW; molecular
weight marker, PC; positive control, whole cell lysate from 293T-transfected cells with human APJ, 1,2,3; lysates from three different mouse
kidneys; red rectangular shapes highlight the main bands erased by the blocking peptide.
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PBS-T three times and then incubated for 45 min with
one of the respective fluorescent secondary antibodies (di-
luted 1:200; Alexa Fluor 488 donkey anti-rat, Alexa Fluor
555 donkey anti-rabbit, Alexa Fluor 647 donkey anti-goat,
and Alexa Fluor 647 donkey anti-mouse IgG; Molecular
Probes, Eugene, OR). Sections were washed three times
and cover slips were placed carefully on top of one drop of
Prolong Gold antifade reagent (Molecular Probes, Eugene,
OR), and sealed with nail polish. Negative controls for
immunofluorescence staining were performed by substitu-
tion of nonimmune serum for the primary antibodies in
adjacent sections (Lambrecht et al. 2006). All slides were
visualized with a Zeiss LSM 510 confocal microscope (Carl
Zeiss, Jena, Germany).
ELISA measurements in urine and plasma
samples
Plasma and urine samples of db/m and db/db mice were
tested for Apelin concentration (pg/ml) using a fluores-
cent enzyme-linked immunosorbent assay (ELISA) direc-
ted against the C-terminus of Apelin-12 (Phoenix
Pharmaceuticals, Belmont, CA) following the manufac-
turer’s protocol. The used kit is designed to detect the
C-terminus of other active forms of Apelin, including
Apelin-36 and Apelin-13 (sensitivity: 15.8 pg/mL).
In urine samples, we also measured Angiotensinogen
(AOG) by a quantitative solid-phase sandwich ELISA
(IBL-America, Minneapolis, MN, sensitivity: 30 pg/mL)
as well as Ang II using an EIA Kit from Cayman Chemi-
cal (Ann Arbor, MN, sensitivity: 1 pg/mL). This assay
had less than 0.001% cross-reactivity with Ang (1–7) and
4% cross-reactivity with Ang I(1–10). Creatinine concen-
tration was assessed using the Jaffe method (Creatinine
Companion, Exocell, Philadelphia, PA) and used for cor-
rection of urinary values of Apelin-12, AOG and Ang II.
For urinary peptide measurements, an aliquot of 100 ll
of freshly collected urine was transferred into tubes kept
on ice at 4°C containing 10X concentrated cocktail of pep-
tidase inhibitors: 25 mmol/L EDTA, 0.44 mmol/L o-phe-
nanthroline, 1 mM chloromercuribenzoic acid (PCMB),
and 120 mmol/L pepstatin A in PBS mixed thoroughly.
The urines with inhibitors were then stored at 80°C until
the extraction. Angiotensin peptides were extracted from
urines using reverse-phase phenyl silica columns (Thermo
Scientific cat. no. 60108-386, 100 mg) according to the
manufacturer’s instructions. Urinary angiotensin II and
Apelin levels were measured using EIA kits.
Cell culture
Conditionally immortalized mouse podocytes generated
by Dr. Peter Mundel (Massachusetts General Hospital,
Boston, MA) were cultured as previously described
(Chen et al. 2004; Lee et al. 2006; Shankland et al.
2007). For the studies, passages 23-28 were used. The
cultured cells exhibited epithelial morphology and were
characterized as podocytes by detection of the podocyte-
specific markers: podocin, synaptopodin, and nephrin,
by immunofluorescence staining (see results). The cells
were allowed to differentiate for at least 2 weeks at 37°C
without c-interferon in DMEM (Gibco Laboratories)
containing 5.5 mmol/L glucose and with 5% heat-inacti-
vated FBS (Gibco Laboratories). The medium was
refreshed every 3 days, and the cells were subcultured
upon confluence. These cells were then used for apopto-
sis and cell signaling studies. For qPCR studies, podo-
cytes (Probetex, San Antonio, TX) were starved 24 h
before measurements at 37°C in a 5% CO2 atmosphere
in 5.5 mmol/L glucose DMEM (low glucose condition,
LG) or 25 mmol/L DMEM (high glucose condition,
HG) without FBS. In a second approach, podocytes
were starved 24 h before measurements under high glu-
cose condition with or without addition of 0.1 lmol/L
of Ang II. In this setting, media were exchanged once
after 12 h. The medium was aspirated after 24 h and
the dishes were washed with 4 mL of ice cold PBS fol-
lowed by RNA extraction by TRIZOL (as described
above). For cell culture studies, the PCR was performed
using a SYBR Green qPCR Master Mix Kit (Thermo
Fischer Scientific, Waltham, MA) by applying standard
cycling parameters and using primers (IDT, Coralville,
IA) specifically designed for this type of qPCR (See
below).
Primers for RT-qPCR
Primer Sequence 50-30
Accession
Number
APJ F TTT GGA GCA GCC GAG AAA AB033170.1
APJ R GTC AAA CTC CCG GTA GGT ATA AG AB033170.1
Apelin F TCC AGA TGG GAA AGG GCT AB023495.1
Apelin R CTG TCT GCG AAA TTT CCT CCT AB023495.1
GADPH F ACT CCC ATT CTT CCA CCT TTG AB017801.1
GADPH R CCC TGT TGC TGT AGC CAT ATT AB017801.1
Cell signaling assays
Activation of cell signaling proteins was evaluated by
western blot using phosphorylation specific antibodies on
podocytes stimulated with Pyr1-Apelin-13. Podocytes were
seeded in 100 mm cell culture plates (~106 cells/plate).
Subconfluent cells were serum-deprived overnight and
then stimulated with Pyr1-Apelin-13 (Bachem, Bubendorf
BL, Switzerland) for 1, 5, 15, and 60 min. Protein was
then extracted using a mammalian protein extraction
reagent (MPER, Pierce) supplemented with protease
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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(Sigma-Aldrich, Saint Louis, MO) and phosphatase
(Roche, Basel, Switzerland) inhibitor cocktails. Lysates
containing equal quantities of total protein were separated
in 10% Bis-Tris Novex precast gels and proteins were
transferred to nitrocellulose membranes (Millipore, Biller-
ica, MA). After blocking, membranes were incubated with
primary antibodies for phospho-specific and total AKT,
p70S6K, and ERK (Cell Signaling) and their correspond-
ing HRP-linked secondary antibodies. Detection of signal
was performed using Amersham ECL Plus reagents, and
films were developed and quantified by densitometry
using ImageJ Software.
Caspase-3 Assay
The assay was performed using a kit from Cayman
Chemical, Ann Arbor, MI Conditionally immortalized
podocytes were serum starved 24 hr before the experi-
ment with RPMI 1640 and 0.2% fetal bovine serum and
seeded onto a 96-well plate. Apelin-13 (100 nmol) was
diluted in RPMI medium with high glucose (25 mM) or
normal glucose (11.1 mmol/L) content and 100 lL of the
solution was put to the cells. Cells were incubated at
37°C overnight in a 5% CO2 atmosphere. The plate was
centrifuged at 800 g for 5 min and medium was aspi-
rated; 200 lL of Caspase-3 assay buffer was added to each
well and the plate was centrifuged again at 800 g for
5 min. After adding 100 lL of cell-based assay lysis buffer
to each well, the plate was placed on an orbital shaker for
30 min at room temperature. The plate was then cen-
trifuged for 10 min at 800 g. The supernatant of each
well (90 lL) was then transferred to a corresponding well
on a black 96 well plate and 10 lL of Caspase-3 Assay
Buffer or 10 lL of Caspase-3 inhibitor solution was
added. Finally, 100 lL of Caspase-3 substrate solution
was pipetted in each well and the plate was incubated for
30 min at 37°C. Activity was measured at 485 nm excita-
tion and 535 nm emission using a microplate fluores-
cence reader FLx800 (Biotek, Winooski, VT).
Effect of AT1-receptor blockade on kidney
APJ and preproapelin mRNA levels
Telmisartan, a specific Ang II receptor antagonist, was
given to db/db mice for 11 weeks starting at the age of
13 weeks. Mice were assigned to drink either tap water
(n = 6) or tap water with telmisartan (Boehringer
Ingelheim, Ingelheim am Rhein, Germany) at a dose of
2 mg*kg1*day1 (n = 6). For telmisartan administra-
tion, mice were weighed and the daily fluid intake per
mouse was recorded to estimate the concentration of
the compound needed to be added to the drinking
water.
Statistical analysis
In all experiments, unless otherwise indicated, data were
reported as mean  SEM with at least three replicates per
group. Pairwise comparisons were performed using two-
tailed t test (for normally distributed data) or Mann–
Whitney test (for not normally distributed data) and a P
value < 0.05 was considered significant.
Results
APJ mRNA and Preproapelin mRNA in mouse
kidney
The relative amount of APJ mRNA and preproapelin
mRNA were evaluated using RT-qPCR in kidneys from
nondiabetic db/m mice (C57BLKS/JLepr). For comparison,
the mRNA levels are reported in relation to those
observed in heart tissue where expression of the APJ
receptor and preproapelin are known to be abundant
(Medhurst et al., 2003). APJ receptor mRNA levels in the
kidney were clearly detectable but only at about 1/8 of the
heart mRNA (1.0  0.7 vs. 7.7  1.9 AU). By contrast,
preproapelin mRNA levels were not significantly different
between kidney and heart (1.0  0.1 vs. 1.6  0.9 AU).
Localization of APJ protein in mouse kidney
To examine which kidney cell types express APJ
immunofluorescent stained sections were evaluated by
confocal microscopy in nondiabetic db/m mice
(C57BLKS/JLepr). To localize APJ within the glomerulus,
we utilized markers of epithelial glomerular cells (podo-
cytes), mesangial and endothelial glomerular cells as pre-
viously described (Ye et al. 2006). Strong colocalization
was found between APJ and nephrin, a podocyte marker
(Fig. 2, top panel). APJ also colocalized with the podocyte
marker synaptopodin, albeit not as strongly as nephrin,
and weakly with podocin, another podocyte maker
(Fig. 2, middle panels). Double-staining with the nuclear
marker WT1, also revealed some cells with APJ colocal-
ization (Fig. 2, bottom panel).
Staining of kidney glomeruli for APJ and PECAM-1
was strictly separated (Fig. 3 panel A), indicating that APJ
is not present in glomerular endothelial cells. Likewise,
APJ showed little colocalization with the mesangial mar-
ker Desmin (Fig. 3, panel B). Further, no colocalization
with the endothelial cell marker PECAM-1 was found in
renal arteries (Fig. 3, panel C). This is in concordance
with absence of APJ in endothelial glomerular cells.
In renal arteries, APJ receptor colocalized with the
smooth muscle marker a-SMA reflecting its presence in
the intima/tunica media as previously described (Pereira
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Figure 2. Immunofluorescence staining of APJ (red; left panels) and the podocyte markers nephrin (green; upper panel), synaptopodin (green,
second panel from the top) and podocin (green, third panel from the top) in a glomerulus from mouse kidney. APJ shows strong colocalization
with nephrin (right upper panel) and synaptopodin, (right second panel) and weaker with podocin (right third panel). The bottom panels show
staining of APJ (red; left) and the podocyte nuclear marker WT1 (green; middle). Double-staining reveals APJ colocalization within WT1-positive
nuclei in some podocytes (right).
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et al. 2013), but there are also areas with the vessel wall
where no colocalization was seen (Fig. 3, panel D).
To localize APJ within tubules, we used ACE2 and
ACE as markers for proximal tubules (Ye et al. 2006) and
aquaporin-2 for principal cells of the collecting tubules
(Fig. 4). APJ colocalized with ACE and ACE2 (Fig. 4,
panels A and B respectively) showing its presence
throughout the proximal tubule. APJ colocalized but
weakly with aquaporin-2 (Fig. 4C).
Studies in cultured podocytes
Staining of cultured podocyte cells showed colocalization
of APJ with podocyte markers (nephrin, synaptopodin
and podocin) (Fig. 5). Nuclear presence of APJ was sug-
gested by double-staining with DAPI, a nuclear marker.
APJ staining was also found outside the nucleus (Fig. 5).
Apelin signaling in cultured podocytes exposed to
apelin-13
After showing expression of APJ in podocytes, we exam-
ined whether there is a functional role of the Apelin sys-
tem in this cell type. The cellular response to Apelin-13
stimulation was determined by measuring the phosphory-
lation status of intracellular signaling proteins in cultured
cells. Cells were stimulated with 100 nM Pyr1Apelin-13.
The ratio of phosphorylated protein to total protein was
determined for Akt, p70S6K, and ERK.
In podocytes, a significant transient increase in phos-
phorylation was seen for all three proteins (Akt, p70S6K,
and ERK) 15 min after stimulation (Fig. 6). After
60 min, the increase subsided completely for ERK and
p70S6K and partially for AKT, showing a dynamic system
of Apelin signaling activity and its deactivation, as previ-
ously shown at similar time points in other cell types
(Masri et al. 2004, 2006).
Effect of Apelin-13 on Caspase-3 activity
Akt and ERK, the two signaling pathways that we found
being activated by Pyr1Apelin-13, have been implicated in
Apelin receptor-mediated suppression of apoptosis (Liu
et al. 2017). We therefore examined whether Apelin-13
exerts an antiapoptotic effect in cultured podocytes under
two glucose concentrations (11.1 mmol/L and, 25 mmol/
L). Caspase-3 activity was significantly higher with 25
than 11.1 mmol/L glucose conditions (21722  5142 vs.
14685  4438 RFU/lg, P < 0.05, n = 7) (Fig. 7). Cas-
pase-3 activity in podocytes with added Apelin-13 did not
differ from activity measured without addition of Apelin-
13 (14285  3189 vs. 14685  4438 RFU/lg, P < 0.05,
n = 7) (Fig. 7). Under the higher glucose concentration
however, addition of Apelin-13 markedly decreased Cas-
pase-3 activity (14655  3517 vs. 21722  5142 RFU/lg,
P < 0.05, n = 7). These findings show that in cultured
podocytes grown in high glucose conditions, stimulation
of APJ by Apelin-13 reduces the proapoptotic effect of
excessive glucose.
Effect of high glucose environment and Ang II on
APJ and preproapelin mRNA expression
RT-qPCR revealed that a HG environment by itself signif-
icantly decreased APJ mRNA, 1.19  0.26 versus
0.56  0.11 (Fig. 8). Preproapelin mRNA also decreased
but not significantly, 1.30  0.24 versus 0.99  0.13,
P > 0.05 (Fig. 8).
Exposure to 0.1 lmol/L Ang II for 24 h significantly
decreased the expression of both APJ and Preproapelin
mRNA under high glucose conditions (APJ: 0.56  0.11
vs. 0.16  0.05, P < 0.05; Preproapelin: 0.99  0.13 vs.
0.51  0.12, P < 0.05). The decrease in mRNA with addi-
tion of Ang II was higher than that achieved by high glu-
cose alone for both preproapelin mRNA and APJ mRNA
(Fig. 8).
Studies in db/db mice and nondiabetic db/m
controls
General and light microscopy findings
These studies were performed in mice of 24–32 weeks of
age. Blood sugar of db/db mice at this timepoint was sig-
nificantly increased as compared to the db/m model. Uri-
nary albumin in db/db mice was significantly increased in
comparison to nondiabetic db/m controls (Table 1). Body
weight and kidney weight were increased in db/db mice,
but the ratio of kidneys/body weight was decreased in db/
db mice as compared to db/m controls, reflecting the pro-
found obesity of the db/db animals.
APJ mRNA, protein abundance, and
immunohistochemistry in db/db mice
APJ mRNA levels were first measured in diabetic db/db
mice in whole kidney extracts by RT- qPCR. Compared
to db/m controls of the same age (8 weeks), APJ mRNA
levels were markedly decreased in db/db mice
(1.0  0.076 vs.  0.36  0.029, n = 7, P < 0.01)
(Fig. 9A). By Western blotting, the relative protein abun-
dance of APJ was also markedly decreased in diabetic db/
db mice as compared to db/m controls (Fig. 9B).
By immunohistochemistry, tubular APJ was also
decreased in db/db mice compared to nondiabetic db/m
controls (1.2  0.1 vs. 1.6  0.1, P < 0.05) (Fig. 9C).
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Figure 3. Immunofluorescence staining of APJ (red; left) and the endothelial cell marker, the platelet-endothelial cell adhesion molecule,
PECAM-1 (green; middle; A) and desmin (green, middle; B) in a kidney glomerulus. APJ shows no colocalization with PECAM-1 (right, A)
and little with desmin (yellow; right, B). Double immunofluorescence staining of APJ (red; left, C) and the endothelial cell marker platelet-
endothelial cell adhesion molecule PECAM-1 (green; middle; C) and the vascular smooth muscle marker, the a-smooth muscle actin, a-SMA
(blue; middle; D) in a renal vessel from mouse kidney. APJ shows no colocalization with PECAM-1 (right), but colocalizes strongly with a-
SMA (pink; right).
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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Figure 4. Immunofluorescence double-staining of APJ (red; left) with ACE (blue; middle; A) and ACE2 (green; middle; B) in proximal tubule (A
and B) as well as with aquaporin2 (green; middle; C) in collecting tubule (C). Images on the right are the digital overlay images (pink or yellow)
for each respective row. APJ shows strong colocalization with ACE and ACE2 throughout the proximal tubule (pink; right panel A and yellow;
right panel B). APJ is also localized in the collecting tubule, but there is very weak colocalization with aquaporin2 (panel C, right).
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APJ DAPI Merge
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Figure 5. The podocytes were triple-label immunostained with antibodies directed against APJ (red; left panels) and the podocyte markers
nephrin, podocin, and synaptopodin (green A through C; middle) and DAPI as a nuclear counterstain (blue, middle, D). Images on the right are
the digital overlay images (yellow or pink) for each respective row. Double-staining shows colocalization of APJ with all three podocyte markers.
APJ colocalizes with a nuclear marker DAPI, but is also found outside of the nucleus. (right, panel D)
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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Time course of signaling after Pyr1-Apelin-13 
stimulation in podocytes
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Figure 6. Time course of phosphorylation for AKT, (upper) p70S6K (middle) and ERK (lower) after stimulation with Pyr1Apelin-13 in cultured
podocytes. Significant transient increases were observed in all three proteins 15 min after stimulation; suffix t – total; prefix p- phosphorylated
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2018 | Vol. 6 | Iss. 23 | e13939
Page 12
ª 2018 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
Apelinergic System in the Kidney T. M€uller et al.
APJ stained weaker in glomerular tufts and a significant
difference could not be found between db/db and db/m
(1.77  0.03 vs. 1.82  0.03, respectively P = 0.2).
Preproapelin mRNA in the kidney and plasma
apelin levels
When compared to db/m controls, mRNA levels of pre-
proapelin were markedly decreased in kidneys from db/
db mice (0.12  0.016 vs. 1.0  0.13 AU, n = 8,
P < 0.01).
Apelin-12 was increased in plasma from db/db mice
when compared to db/m controls (1.241  0.175 vs.
0.786  0.072 ng/ml, n = 6, P < 0.05). Apelin-12 in the
urine from db/db mice was also increased when com-
pared to db/m (1115.0  323 vs. 504.4  319 pg/mg cre-
atinine, n = 12 for db/db and n = 8 for db/m), although
this difference did not reach statistical significance
(P = 0.054).
Urine Angiotensinogen and Ang II in db/db mice
In db/db mice of 8 weeks of age, urine Ang II (normal-
ized by urine creatinine) was significantly higher when
compared with db/m (203  54 vs. 45  13 vs. pg/mg
creatinine, P < 0.05). Angiotensinogen (AOG) concentra-
tion normalized by creatinine was also significantly higher
in db/db mice than in db/m controls (41.2  9.7 vs.
5.9  1.7 ng/mg creatinine, P < 0.05). Both may be
attributed to an activation of the local kidney renin–an-
giotensin system in diabetic mouse models (Wysocki
et al. 2017a). Albumin/creatinine ratio was significantly
higher in db/db than in db/m controls (303.4  32.1,
n = 25 vs. 87.3  4.3 lg/mg, n = 15 respectively,
P < 0.01).
Effect of Telmisartan on APJ in db/db kidney
Kidney APJ mRNA expression in db/db mice treated with
telmisartan for 11 weeks was significantly higher as com-
pared to untreated db/db mice (2.48  0.51 vs.
0.95  0.16 AU, n = 6 both groups, P < 0.01) (Fig. 10A).
Kidney preproapelin mRNA was also significantly
increased in kidneys from mice treated with telmisartan
(5.41  1.51 vs. 0.83  0.11 AU, n = 6 both groups,
P < 0.05) (Fig. 10).
Discussion
In this report, we examined the distribution of APJ in the
kidney and demonstrated that within the glomerulus the
receptor is localized in epithelial glomerular cells (podo-
cytes) but not in glomerular endothelial cells and only
very weakly in mesangial cells. Further, APJ was also
abundantly present in proximal tubules, and renal vascu-
lature, as previously described (O’Carroll et al. 2000). In
diabetic db/db mice, we found that the overall expression
of APJ was depressed at the mRNA level and also at the
protein level both by Western Blot and by immunohisto-
chemistry.
In cultured podocytes, Apelin-13 stimulated APJ trig-
gering the activation of Akt, Erk, and p70S6K pathways.
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normal glucose (NG) or high glucose medium (HG) with apelin-13
(light gray, with Ape-13) or without addition of apelin-13 (dark
gray, w/o Ape-13). Caspase-3 activity was significantly increased in
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Figure 8. Relative mRNA levels of preproapelin (APLN, left) and
APJ (right) in cultured podocytes in normal glucose medium (NG),
high glucose medium (HG) or high glucose medium with 0.1 lmol/
L of Ang II (HG+ANGII). APJ mRNA was significantly decreased by
HG, whereas preproapelin decreased but not significantly. Both APJ
and preproapelin decreased significantly under HG with addition of
Ang II; *P < 0.05; **P < 0.01.
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The pattern of activation by apelin was brief and transient
as previously described in other cell types, such as
smooth muscle cells, neurons, adipocytes, and osteoblasts
(Chaves-Almagro et al. 2015). The Akt pathway has been
described to activate endothelial nitric oxide synthase
(eNOS), which is responsible for the vasodilatory effect of
Apelin in vessels (Jia et al. 2007; Japp et al. 2008). Inter-
estingly, within the podocytes the expression pattern was
Table 1. Characteristics of db/m and db/db mice at 24–32 weeks of age.
db/m db/db
Blood glucose (mmol/L) 163  9 530  41
Body weight (g) 27.8  0.5 49.5  2.0*
Kidney weight (mg) 154  9 206  6*
Ratio kidneys/body weight (mg/g) 5.6  0.4 4.2  0.2*
Albumin/Creatinine ratio (lg/mg) 7.3  2.0 (5) 613.3  366.0* (5)
Mesangial matrix expansion 0.60  0.24 (5) 2.20  0.20* (5)
Glomerular cellularity 0.6  0.24 (5) 1.8  0.20* (5)
Glomerular tuft area (lm2) 2804.2 111 (5) 3931.5  252.6* (5)
Podocyte count (per glomerulus) 13.1  0.3 (8) 10.0  0.4* (8)
db/m control mice; db/db diabetic mice (n = 7 and n = 6 respectively, unless stated otherwise); Data are expressed as means  SE.
*P < 0.05 db/m versus db/db mice by Mann–Whitney test; Optical histology: mesangial matrix expansion and glomerular cellularity, were eval-
uated on H&E and PAS sections by a renal pathologist. Podocyte count was performed by counting WT-1 stained nuclei in a blinded fashion
by two independent investigators.
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Figure 9. mRNA (A) and protein levels of APJ receptor by Western Blot (B) in whole kidney extracts of db/m and db/db mice. APJ receptor
protein (42 kD) was normalized to the mouse b-tubulin (55 kD) (B). APJ mRNA and protein levels are significantly decreased in db/db mice. The
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db (right). APJ staining (dark brown) is seen in tubules and to lesser extent in glomeruli. Staining was stronger in db/m as compared to db/db
mice.
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both nuclear as well as in the plasma membrane, as
expected for a G protein-coupled receptor (Lee et al.
2004).
We also found that apoptosis through activation of
Caspase-3 was increased in podocytes when they were
exposed to a high glucose environment, confirming the
data reported by Langer et al. (2016). We used Caspase-3
activity as a marker of podocyte apoptosis, which is con-
sidered an early manifestation of diabetic lesions in kid-
neys from mouse models, such as the db/db (Susztak
et al. 2006). Here, we show for the first time that stimula-
tion by Apelin-13 leads to a reduction of the otherwise
elevated Caspase-3 activity in high glucose environment
in podocytes (Fig. 7). This decrease in Caspase-3 activity
in podocytes by Apelin-13 is in accordance with similar
antiapoptotic effects of the peptide in human and mouse
osteoblasts (Tang et al. 2007; Xie et al. 2007), rat car-
diomyocytes (Zhang et al. 2009), and rat brain tissue
(Khaksari et al. 2012). Others have shown that Apelin
affects cell survival by directly suppressing apoptosis (Liu
et al. 2017). Together with activation of antioxidant
enzymes like catalase (Nishida and Hamaoka 2013),
reduction of Caspase-3 activity may partially account for
the renoprotective effect of the apelinergic system in
DKD which has been previously reported by Day, Cava-
glieri, and Feliers (Day et al. 2013). Importantly, in this
study administration of Apelin-13 to diabetic mice ame-
liorated DKD and upregulated kidney APJ (Day et al.
2013). Taking into account the localization of APJ in
podocytes and Caspase-3 suppression by Apelin-13 in
these cells, it is likely that stimulation of a podocyte ape-
linergic system accounts, at least in part, for the reported
beneficial effects of this peptide in DKD.
In cultured podocytes, we showed that high glucose
downregulates APJ mRNA levels and this effect is mark-
edly accentuated by exposure to Ang II (Fig. 8). These
findings prompted us to study the effect of diabetes
in vivo on kidney APJ expression in the db/db mouse
model of DKD. In these animals, urinary albumin excre-
tion was increased as previously reported (Hummel et al.
1966; Sharma et al. 2003) and glomerular mesangial
expansion was present as well as an increase in the
glomerular tuft area in glomeruli from both cortex and
juxtamedullary region. A causative role of suppressed APJ
expression in the development of DKD requires further
evidence but several findings suggest its important role.
The proapoptotic action of high glucose, as inferred by
Caspase-3 activity, was suppressed by simulation of APJ
with apelin-13 in cultured podocytes. We also showed
that Ang II downregulates both APJ and preproapelin in
podocytes exposed to high glucose. In the db/db model,
like in other models of DKD in mice and humans
Figure 10. mRNA of APJ and Preproapelin measured by RT PCR in kidney lysates from untreated db/db mice and db/db mice given
telmisartan, a specific AT1 blocker for 11 weeks (n = 6 per group); *P < 0.05.
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(Tamura et al. 2005; Peti-Peterdi et al. 2008; Umemoto
et al. 2016; Wysocki et al. 2017a,b), the kidney RAS is
overactive as reflected by high levels of urinary
angiotensinogen and Ang II. This upregulation is at least
partially attributable to stimulation by the high glucose
environment (Wolf 2004; Peti-Peterdi et al. 2008). Over-
all, our data suggest that high glucose and high Ang II
activity may converge to suppress APJ in podocytes and
contribute to the development of the glomerular lesions
of DKD and its progression.
The suppression of APJ and preproapelin that we found
in podocytes was previously described in different tissues
such as adipocytes and cardiomyocytes, which was
reported to be dose-dependent and mediated by the AT1-
receptor (Iwanaga et al. 2006; Wu et al. 2014). The com-
bination of high glucose and high levels of Ang II
achieved a higher level of APJ and preproapelin downregu-
lation than the high glucose environment alone (Fig. 8).
This synergistic effect may explain the low level of APJ
observed in the db/db mouse model of DKD where we
found that the RAS is overactive at the kidney level (i.e.,
increased urinary AOG and Ang II). Overactivity of the
kidney RAS is a feature of other models of DKD and
human DKD (Tamura et al. 2005; Peti-Peterdi et al.
2008; Umemoto et al. 2016; Wysocki et al. 2017a,b; Pat-
ney et al. 2018). Possibly downregulation of the kidney
APJ is, at least in part, the consequence of hyperglycemia
and RAS overactivity at the tissue level.
Of interest, specific AT1 blockade with telmisartan
resulted in an increase in the APJ and preproapelin mRNA
in db/db mice. Upregulation of these two major compo-
nents of the apelinergic system, APJ and preproapelin,
may be yet another beneficial effect of AT1-blockers
beyond AT1-inhibition.
In conclusion, the present study shows that in the kid-
ney glomerulus the apelin receptor is preferentially local-
ized in podocytes. In cultured podocytes, high glucose
and Ang II decrease APJ expression at the mRNA level
while the apoptotic effect of high glucose can be reversed
by stimulation of APJ by one of its main ligands Apelin-
13. In diabetic db/db mice kidney, APJ expression is
markedly decreased at the mRNA level and protein level.
Altogether our findings suggest a role for APJ downregu-
lation in the development of DKD. The half-life of ape-
lin-13 and other apelins is short (minutes) but with the
development of apelin agonists with prolonged half-life
(Juhl et al. 2016; Huang et al. 2018), the podocyte apelin-
ergic system may become a good target for the treatment
of DKD.
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